[email protected]

01252 375362

01252 375362

  • About Us
    • About Pharmacy Consulting
    • Our Team
    • Work with us
    • Testimonials
  • Consultancy
    • For Pharmaceutical Wholesalers
    • For Pharmacies
    • Care Quality Commission – CQC
    • Pharmaceutical Manufacturers
    • Medical Devices Consultancy and Training
  • Flexible Training
    • Good Distribution Practice (GDP) Training
    • RPi Training
    • Licence Holder Training
    • Export Training
    • Audit Training
    • Active Pharmaceutical Ingredient (API) and Clinical Trials Training
    • Superintendent Pharmacist Training
    • GPhC Guidance for Online Pharmacies
  • RP Cogent GDP Training
  • RP Forum
  • Training Calendar
  • Our CPD
    • Blog
    • Editorial Items
    • Social Media
  • Contact Us
Risk Assessments – Evaluating hazards

Risk Assessments – Evaluating hazards

by Charlotte Abbott | Jul 22, 2021 | Blog, Risk Assessments

Risk Assessments: The aim of writing one is to evaluate hazards, then remove that hazard or minimise the level of its risk by adding control measures, as necessary.

WDA(H) & Import – New Guidelines:

WDA(H) & Import – New Guidelines:

by Sally Finlayson | Jul 21, 2021 | Blog, Brexit, GDP/RP, MHRA, RP, Training, WDA(H)

Following Brexit and GB leaving the EU the MHRA have advised that GB wholesale dealers now need to appoint an RPi

API registration

API registration

by Steven Hewison | Jul 21, 2021 | API Registration, Blog

API registration is an MHRA requirement if you manufacture, import or distribute active substances and you are based in the UK.

New Contract RP introduction

New Contract RP introduction

by Steven Hewison | Jul 21, 2021 | Blog, MHRA, RP

New Contract RP says hello! Please allow me to introduce myself as the newest member of PCL’s Contract RP Team.

Export & WDA(H) – Updated Guidelines:

Export & WDA(H) – Updated Guidelines:

by Sally Finlayson | Jul 14, 2021 | Blog, Export Training, MHRA, WDA(H), WDA(H)

As Great Britain (GB) are no longer part of the European Union (EU) since the 1st of January 2021 exit date. It is essential to ensure all the necessary changes have been made to remain MHRA compliant.

Refrigerated Medicinal Products – what to consider…

Refrigerated Medicinal Products – what to consider…

by Sally Finlayson | Jul 13, 2021 | Blog, Export Training, Good Distribution Practice - GDP

How do you manage YOUR refrigerated medicinal products? Check out 10 key points to ensure you are shipping your products effectively

« Older Entries
Next Entries »

Recent Posts

  • Professional Indemnity Insurance
  • FDA Warning Letters
  • Emerging issues – Communique from the GPhC

Upcoming Courses

  • RP Forum – GxP Certificates for Customers and Supplier Qualification on 9 September 2025 10:00 am
  • Introduction to Good Distribution Practice Online Training on 10 September 2025 10:00 am
  • GDP/RP Cogent Gold Standard Online Training on 16 September 2025
  • GDP Audit Online Training on 1 October 2025 10:00 am
  • Licence Holder Training on 14 October 2025 10:00 am

MHRA Alerts & Recalls

Field Safety Notices: 5 to 9 May 2025
21 August 2025
Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets, Chanelle Medical Unlimited Company, EL(25)A/41
21 August 2025
Field Safety Notices: 11 to 15 August 2025
19 August 2025
Class 4 Medicines Defect Notification: Levetiracetam Accord 100mg/ml oral solution, Accord Healthcare Limited, UK, EL(25)A/40
14 August 2025

Get In Touch

Address:
Wellesley House
10 Eelmoor Road
Farnborough
Hampshire
GU14 7QN

Phone: 01252 375362
Email: [email protected]
  • Terms and Conditions
  • Privacy Policy

Designed by Four Lakes

  • Follow
  • Follow
  • Follow
  • Follow